TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32538005

Group type: EXPERIMENTAL
Intervention: Balance acupuncture therapy combined with exercise re-learning rehabilitation therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 90
Study: 35379469

Group type: EXPERIMENTAL
Intervention: Modified biblock MAA with elastics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monoblock MAA
Number of subjects: 20
Study: 34591105

Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine with information on effectiveness at preventing death from COVID-19
Number of subjects: 2556

Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine with information on overall effectiveness at preventing symptomatic transmission
Number of subjects: 2556

Group type: EXPERIMENTAL
Intervention: Johnson & Johnson vaccine with information on effectiveness at preventing death from COVID-19
Number of subjects: 2556

Group type: EXPERIMENTAL
Intervention: Johnson & Johnson vaccine with information on overall efficacy at preventing symptomatic infection
Number of subjects: 2556
Study: 32855874

Group type: EXPERIMENTAL
Intervention: InVitria
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional freehand technique
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional freehand technique (senior surgeons)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional freehand technique (junior surgeons)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: InVitria (senior surgeons)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: InVitria (junior surgeons)
Number of subjects: 140
Study: 35314014

Group type: EXPERIMENTAL
Intervention: CUPS program (integrated nutrition and mathematics curriculum)
Number of subjects: 18
Study: 37421852

Group type: EXPERIMENTAL
Intervention: EVOO (rich oleocanthal and oleacein extra virgin olive oil)
Number of subjects: 91

Group type: COMPARATOR
Intervention: OO (common olive oil)
Number of subjects: 91
Study: 32062728

Group type: EXPERIMENTAL
Intervention: Individualized antipsychotic dose reduction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous maintenance treatment
Number of subjects: 20
Study: 36161830

Group type: EXPERIMENTAL
Intervention: Ranibizumab (induced group)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Sham (native group)
Number of subjects: 367
Study: 33403878

Group type: EXPERIMENTAL
Intervention: CysC measurement with different reagents and instruments (CysC reagent: Whitman, Nanjing, China)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (healthy subjects with RF concentration <11.1 IU/mL)
Number of subjects: 63
Study: 32749561

Group type: COMPARATOR
Intervention: Mechanical brushing (MB)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Association of mechanical brushing with oral irrigation (WP)
Number of subjects: 38
Study: 32021150

Group type: EXPERIMENTAL
Intervention: Endurance exercise training and virtual reality training (ET+VR)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Virtual reality training (VR)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Endurance exercise training (ET)
Number of subjects: 106
Study: 35859328

Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (rhG-CSF when WBC < 2.0 × 10^9/L or ANC < 1.0 × 10^9/L)
Number of subjects: 130
Study: 32255178

Group type: EXPERIMENTAL
Intervention: PASS group
Number of subjects: 60

Group type: COMPARATOR
Intervention: MBT group
Number of subjects: 60
Study: 35285851

Group type: EXPERIMENTAL
Intervention: Accessible care
Number of subjects: 167

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 167
Study: 32651161

Group type: EXPERIMENTAL
Intervention: Aldesleukin 2 MIU
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aldesleukin 1 MIU
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aldesleukin (both doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aldesleukin (all doses)
Number of subjects: 36
Study: 36470777

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training (including digital operating system training, music therapy, aerobic training, and mental health intervention) for 6 months
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training
Number of subjects: 136
Study: 33740084

Group type: EXPERIMENTAL
Intervention: Thunderbeat
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard instrumentation
Number of subjects: 72
Study: 32090123

Group type: EXPERIMENTAL
Intervention: Humalog Mix 50
Number of subjects: 102

Group type: COMPARATOR
Intervention: Novo Mix 30
Number of subjects: 102
Study: 35572853

Group type: EXPERIMENTAL
Intervention: LT3 monotherapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: LT4 monotherapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: LT3 treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: LT4 treatment
Number of subjects: 59
Study: 34420980

Group type: EXPERIMENTAL
Intervention: Eteplirsen treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard of care (SOC) external controls
Number of subjects: 22

Group type: COMPARATOR
Intervention: Natural history study patients
Number of subjects: 22
Study: 32584065

Group type: EXPERIMENTAL
Intervention: Randomized planned missingness design in daily diary study
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Routine randomization of item display and order, timing and frequency of measurement
Number of subjects: 1300
Study: 34979943

Group type: EXPERIMENTAL
Intervention: Patient-controlled paravertebral-block analgesia (PBA)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PIA)
Number of subjects: 338
Study: 33999547

Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion during cardiac surgery
Number of subjects: 4770

Group type: COMPARATOR
Intervention: No left atrial appendage occlusion during cardiac surgery (control)
Number of subjects: 4770
Study: 32836220

Group type: EXPERIMENTAL
Intervention: Aflibercept treatment (1 dose)
Number of subjects: 125
Study: 35029235

Group type: EXPERIMENTAL
Intervention: Game-based circuit exercise
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional circuit exercise
Number of subjects: 82
Study: 33475403

Group type: EXPERIMENTAL
Intervention: Positive clip
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral clip
Number of subjects: 60
Study: 34809573

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 8 mg with bupivacaine 0.25% 40 ml (Group TAPD)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 40 ml (Group TAPA)
Number of subjects: 58
Study: 32129681

Group type: EXPERIMENTAL
Intervention: Aspirin plus rivaroxaban (2.5 mg b.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin (81 mg q.d.)
Number of subjects: 30
Study: 35834470

Group type: EXPERIMENTAL
Intervention: Engager intervention (one-to-one support)
Number of subjects: 24
Study: 35010961

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3 per day (VDD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 per month (VDM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nothing (Control - CON)
Number of subjects: 100
Study: 36082423

Group type: EXPERIMENTAL
Intervention: Decision support intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 34238526

Group type: EXPERIMENTAL
Intervention: Monopolar dielectric transmission of pulsed electromagnetic fields (PEMF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 32947455

Group type: EXPERIMENTAL
Intervention: Guided Exercise Therapy (GET)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Self-Organized Activity (SOA)
Number of subjects: 111
Study: 35116266

Group type: EXPERIMENTAL
Intervention: Extended field-IMRT with concurrent cisplatin chemotherapy (40 mg/m2)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Pelvic-IMRT with concurrent cisplatin chemotherapy (40 mg/m2)
Number of subjects: 129
Study: 32705821

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 34011351

Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 36294019

Group type: EXPERIMENTAL
Intervention: Nutrition Counselling (NC)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Nutrition Counselling combined with Unconditional Cash Transfer (NC + UCT)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study: 33901941

Group type: EXPERIMENTAL
Intervention: 3-month web-based transitional care program
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study: 32843084

Group type: EXPERIMENTAL
Intervention: Fire needle therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fire needle control therapy
Number of subjects: 92
Study: 33347022

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study: 33419261

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34256014

Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-fermented-food diet
Number of subjects: 36
Study: 34931438

Group type: EXPERIMENTAL
Intervention: pTGV prediction model
Number of subjects: 181
Study: 33710426

Group type: EXPERIMENTAL
Intervention: Digital ethnography analysis of online posts
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Online communities for support
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Digital ethnography
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Comparison to prior work
Number of subjects: 1867
Study: 34826819

Group type: EXPERIMENTAL
Intervention: NSAIDs (parecoxib injection and subsequent loxoprofen tablets)
Number of subjects: 202
Study: 32960662

Group type: EXPERIMENTAL
Intervention: 7‐days‐a‐week accelerated postoperative radiotherapy (p‐CAIR)
Number of subjects: 111

Group type: COMPARATOR
Intervention: postoperative radio‐chemotherapy (p‐RTCT)
Number of subjects: 111
Study: 36332959

Group type: EXPERIMENTAL
Intervention: Emotive and educational seminars on medical ethics
Number of subjects: 419

Group type: COMPARATOR
Intervention: General medical topics seminars (Control)
Number of subjects: 419
Study: 35193165

Group type: EXPERIMENTAL
Intervention: Exercise in the heat (40°C, 52% relative humidity)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sauna (55°C, 54% relative humidity)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hot water immersion (40°C)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Thermoneutral water immersion (36.5°C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All modes of heat
Number of subjects: 13
Study: 32107889

Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (CAP-B)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Observation until first disease progression (PD1)
Number of subjects: 221
Study: 35361348

Group type: EXPERIMENTAL
Intervention: Experimental sleep restriction (4 hour sleep opportunity)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control sleep (9 hour sleep opportunity)
Number of subjects: 12
Study: 33241466

Group type: EXPERIMENTAL
Intervention: 1.5% levofloxacin with 0.1% fluorometholone administered four times a day
Number of subjects: 19

Group type: COMPARATOR
Intervention: sixfold dilution of polyvinyl alcohol iodine (PAI) solution with 0.1% fluorometholone four times a day
Number of subjects: 19
Study: 35121271

Group type: EXPERIMENTAL
Intervention: Face to face (FtF) therapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Digital (dCBT-I) therapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both FtF and dCBT-I
Number of subjects: 101
Study: 33303654

Group type: EXPERIMENTAL
Intervention: RAAS inhibitors (RAASi)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 576
Study: 33438897

Group type: EXPERIMENTAL
Intervention: Positive result studies (185 studies, 64.2%)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Negative result studies (103 studies, 35.8%)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Studies with larger sample sizes
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Studies classified as positive result
Number of subjects: 288
Study: 33023491

Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg neostigmine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg neostigmine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 132
Study: 35685192

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with chorion membrane (CAF+CM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Coronally advanced flap with connective tissue graft (CAF+CTG)
Number of subjects: 8
Study: 34551959

Group type: EXPERIMENTAL
Intervention: FeverPAIN ≥4
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Centor ≥3
Number of subjects: 565
Study: 32818625

Group type: EXPERIMENTAL
Intervention: Germline genetic factors and polygenic/multifactorial risk scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rare high-penetrance variants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telomere length and mitochondrial DNA copy number
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common variants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetics of pancreatic neuroendocrine tumors (PNET)
Number of subjects: 0
Study: 35700594

Group type: EXPERIMENTAL
Intervention: Taurine (1.5 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (1.5 g of starch)
Number of subjects: 24
Study: 37227388

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10137
Study: 34303491

Group type: EXPERIMENTAL
Intervention: Intraoperative HPI-guided care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard haemodynamic care
Number of subjects: 60
Study: 32925975

Group type: EXPERIMENTAL
Intervention: Uncorrected visual impairment (VA ≤ 6/12)
Number of subjects: 4985

Group type: EXPERIMENTAL
Intervention: Presenting visual impairment (VA ≤ 6/12)
Number of subjects: 4985

Group type: EXPERIMENTAL
Intervention: Best-corrected visual impairment (VA ≤ 6/12)
Number of subjects: 4985

Group type: EXPERIMENTAL
Intervention: Refractive error as a cause of impaired vision
Number of subjects: 4985

Group type: EXPERIMENTAL
Intervention: Myopia (≤ -0.5 D)
Number of subjects: 4985

Group type: EXPERIMENTAL
Intervention: Hyperopia (≥ +2.0 D)
Number of subjects: 4985

Group type: EXPERIMENTAL
Intervention: Astigmatism (≥ 0.75 D)
Number of subjects: 4985
Study: 35727442

Group type: EXPERIMENTAL
Intervention: ProxiMAX randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAX randomization
Number of subjects: 0
Study: 33608712

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Tamoxifen for 2 years followed by Anastrozole for 3 years
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: PAM-50 analysis
Number of subjects: 1204
Study: 33104739

Group type: EXPERIMENTAL
Intervention: Labelled scenarios
Number of subjects: 0

Group type: COMPARATOR
Intervention: Descriptive scenarios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Satisfaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predisposition to seek healthcare
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attributing illness to bad luck
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concern about the health condition
Number of subjects: 0
Study: 35484039

Group type: EXPERIMENTAL
Intervention: MucoRice-CTB vaccine (6-g dose)
Number of subjects: 9
Study: 33846198

Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard of care (SOC) with chemotherapy
Number of subjects: 0
Study: 35532915

Group type: EXPERIMENTAL
Intervention: Compound intervention with digital scales, electronic pill bottles, and regret lottery incentives ($1.40 expected daily value)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Compound intervention
Number of subjects: 552
Study: 33670797

Group type: EXPERIMENTAL
Intervention: Long-term midwife-led breastfeeding support
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Psychosocial support
Number of subjects: 1080
Study: 36352602

Group type: EXPERIMENTAL
Intervention: Yoga as a complementary treatment for epilepsy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Studies describing knowledge, attitude, influence, and practice of yoga in epilepsy
Number of subjects: 15
Study: 35965789

Group type: EXPERIMENTAL
Intervention: Yun-type training
Number of subjects: 150

Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 150
Study: 33152686

Group type: EXPERIMENTAL
Intervention: Light exposure and sleep hygiene intervention (INT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20
Study: 35274222

Group type: EXPERIMENTAL
Intervention: 5 mg warfarin
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3 mg warfarin
Number of subjects: 50
Study: 33889958

Group type: EXPERIMENTAL
Intervention: Genetically predicted plasma LRG1 levels (associated with rs4806985 variant)
Number of subjects: 3694

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 3694
Study: 35271811

Group type: EXPERIMENTAL
Intervention: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection (higher doses)
Number of subjects: 28

Group type: COMPARATOR
Intervention: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection (lower doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection
Number of subjects: 28
Study: 33017530

Group type: EXPERIMENTAL
Intervention: 35% baking soda toothpaste
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: 20% baking soda toothpaste
Number of subjects: 319

Group type: COMPARATOR
Intervention: Fluoride toothpaste control
Number of subjects: 319
Study: 36180152

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM) adductor stretch
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Myofascial release
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Conventional stretching
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 32778521

Group type: EXPERIMENTAL
Intervention: HA‐WBRT (30 Gy/10 fractions)
Number of subjects: 34
Study: 34274079

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) given 45 minutes before training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no caffeine)
Number of subjects: 30
Study: 32032307

Group type: EXPERIMENTAL
Intervention: Culture-negative late-onset sepsis (LOS)
Number of subjects: 1505
Study: 36029771

Group type: EXPERIMENTAL
Intervention: Human-derived fortifier (H2MF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bovine-derived human milk fortifier (BHMF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mother's own milk (MOM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxidative stress (urinary F2‐isoprostanes)
Number of subjects: 30
Study: 32052214

Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB LA)
Number of subjects: 0
Study: 35799365

Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch (C8P)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control low dose Capsaicin 0.025% patch (CON)
Number of subjects: 11
Study: 32692284

Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS) prediction
Number of subjects: 1787

Group type: EXPERIMENTAL
Intervention: Nomogram for cancer-specific survival (CSS) prediction
Number of subjects: 1787

Group type: EXPERIMENTAL
Intervention: Nomogram prediction
Number of subjects: 1787

Group type: EXPERIMENTAL
Intervention: New predictive model
Number of subjects: 1787
Study: 34009520

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser with low fluence and low density (800-µm tip, 5% density, 10 mJ fluence, single pass)
Number of subjects: 40
Study: 33567505

Group type: EXPERIMENTAL
Intervention: Higher glycine concentrations
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Higher linoleic acid concentrations
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sucrose concentrations
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sphingomyelins (C32:2, C38:1) concentrations
Number of subjects: 151
Study: 32208844

Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clipping
Number of subjects: 0
Study: 36285763

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Imported doses from Héma-Québec
Number of subjects: 394

Group type: COMPARATOR
Intervention: Transferred doses between CBS regional distribution centers
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Transfusions at hubs and spoke sites
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Equitable allocation model
Number of subjects: 394
Study: 35010391

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Acceptance‐Commitment (MAC) program (n = 20; 7 group sessions, 60 min each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active control group (n = 20; 7 group sessions, 60 min each)
Number of subjects: 40
Study: 35922380

Group type: EXPERIMENTAL
Intervention: Immersive VR‐ABM
Number of subjects: 120

Group type: COMPARATOR
Intervention: Desktop VR‐ABM
Number of subjects: 120

Group type: COMPARATOR
Intervention: Immersive VR‐game
Number of subjects: 120
Study: 33158824

Group type: EXPERIMENTAL
Intervention: e-PROMs data capture and feedback
Number of subjects: 63
Study: 34850776

Group type: EXPERIMENTAL
Intervention: Novel irradiation stent (NIS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional irradiation stent (CIS)
Number of subjects: 94
Study: 34101389

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 40 mg/m2
Number of subjects: 77

Group type: COMPARATOR
Intervention: Three-weekly cisplatin 100 mg/m2
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study: 34373299

Group type: EXPERIMENTAL
Intervention: Perx app
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124